These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36218067)

  • 41. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
    Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
    Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
    Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
    J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The antiandrogenic effect of finasteride against a mutant androgen receptor.
    Wu Y; Chhipa RR; Zhang H; Ip C
    Cancer Biol Ther; 2011 May; 11(10):902-9. PubMed ID: 21386657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
    Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
    J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
    Jang YG; Go RE; Hwang KA; Choi KC
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
    Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
    Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT; Wilson EM; Shapiro DJ
    J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
    Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
    Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
    Hua Y; Shun TY; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
    Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptide antagonist of the androgen receptor.
    Gao W
    Curr Pharm Des; 2010; 16(9):1106-13. PubMed ID: 20030610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization.
    Jones JO; An WF; Diamond MI
    ACS Chem Biol; 2009 Mar; 4(3):199-208. PubMed ID: 19236099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation.
    El Kharraz S; Dubois V; van Royen ME; Houtsmuller AB; Pavlova E; Atanassova N; Nguyen T; Voet A; Eerlings R; Handle F; Prekovic S; Smeets E; Moris L; Devlies W; Ohlsson C; Poutanen M; Verstrepen KJ; Carmeliet G; Launonen KM; Helminen L; Palvimo JJ; Libert C; Vanderschueren D; Helsen C; Claessens F
    EMBO Rep; 2021 Dec; 22(12):e52764. PubMed ID: 34661369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.